Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine and BMT for Relapsed/Refractory AML/MDS
NCT01707004Phase 2Completed
- Sponsor
- University of Wisconsin–Madison
- Start
- May 2013
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of decitabine in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by University of Wisconsin–Madison. Started May 2013; status: completed.
02
Drugs
decitabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01707004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01707004.